| Identification | More | [Name]
Cyclopenthiazide | [CAS]
742-20-1 | [Synonyms]
CYCLOPENTHIAZIDE
NAVIDREX
2h-1,2,4-benzothiadiazine-7-sulfonamide,6-chloro-3-(cyclopentylmethyl)-3,4-dih
3-cyclopentylmethylhydrochlorothiazidederiv
cyclomethiazide
navidrix
salimed
salimid
su8341
tsiklometiazid
ydro-,1,1-dioxide
6-chloro-3-cyclopentylmethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide
6-Chloro-3-[cyclopentylmethyl]-3,4-dihydro-[2H]-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
Cyclopentiazide
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-, 1,1-dioxide (6CI, 8CI, 9CI)
6-Chloro-3-(cyclopentylmethyl)-3,4-dihydro-7-sulfamyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
6-Chloro-3-cyclopentylmethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
Ciba 8341-Su
Cyclometiazid | [EINECS(EC#)]
212-012-5 | [Molecular Formula]
C13H18ClN3O4S2 | [MDL Number]
MFCD00865825 | [Molecular Weight]
379.88 | [MOL File]
742-20-1.mol |
| Hazard Information | Back Directory | [Uses]
Antihypertensive;Sodium Chloride Symporter Inhibitor | [Uses]
Cyclopenthiazide is a thiazide diuretic. Cyclopenthiazide is used in the treatment of oedema caused by conditions such as kidney disease, liver cirrhosis and pre-menstrual syndrome as well as in the treatment of hypertension. | [Definition]
ChEBI: 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide is a benzothiadiazine. | [World Health Organization (WHO)]
Cyclopenthiazide, a thiazide diuretic, was introduced in 1968. It
continues to be used mainly in combination drugs. | [Clinical Use]
Thiazide diuretic:
Hypertension
Heart failure
Oedema | [Drug interactions]
Potentially hazardous interactions with other drugs
Analgesics: increased risk of nephrotoxicity with
NSAIDs; antagonism of diuretic effect. Anti-arrhythmics: hypokalaemia leads to increased
cardiac toxicity; effects of lidocaine and mexiletine
antagonised.
Antibacterials: avoid administration with
lymecycline.
Antidepressants: increased risk of hypokalaemia
with reboxetine; enhanced hypotensive effect with
MAOIs; increased risk of postural hypotension with
tricyclics.
Antiepileptics: increased risk of hyponatraemia with
carbamazepine.
Antifungals: increased risk of hypokalaemia with
amphotericin.
Antihypertensives: enhanced hypotensive effect;
increased risk of first dose hypotension with postsynaptic alpha-blockers like prazosin; hypokalaemia
increases risk of ventricular arrhythmias with sotalol.
Antipsychotics: hypokalaemia increases risk
of ventricular arrhythmias with amisulpride;
enhanced hypotensive effect with phenothiazines;
hypokalaemia increases risk of ventricular
arrhythmias with pimozide - avoid.
Atomoxetine: hypokalaemia increases risk of
ventricular arrhythmias.
Cardiac glycosides: increased toxicity if hypokalaemia
occurs.
Ciclosporin: increased risk of nephrotoxicity and
possibly hypomagnesaemia.
Cytotoxics: increased risk of ventricular arrhythmias
due to hypokalaemia with arsenic trioxide; increased
risk of nephrotoxicity and ototoxicity with platinum
compounds.
Lithium: excretion reduced, increased toxicity | [Metabolism]
Cyclopenthiazide appears to be entirely excreted
unchanged in the urine. |
|
|